Orth, Hans Martin
Flasshove, Charlotte
Berger, Moritz
Hattenhauer, Tessa
Biederbick, Kaja D.
Mispelbaum, Rebekka
Klein, Uwe
Stemler, Jannik
Fisahn, Matthis
Doleschall, Anna D.
Baermann, Ben-Niklas
Koenigshausen, Eva
Tselikmann, Olga
Killer, Alexander
de Angelis, Clara
Gliga, Smaranda
Stegbauer, Johannes
Spuck, Nikolai
Silling, Gerda
Rockstroh, Jürgen K.
Strassburg, Christian P.
Brossart, Peter
Panse, Jens P.
Jensen, Björn-Erik Ole
Luedde, Tom
Boesecke, Christoph
Heine, Annkristin
Cornely, Oliver A.
Monin, Malte B. http://orcid.org/0000-0002-8794-3612
Funding for this research was provided by:
Universitätsklinikum Bonn
Article History
Received: 13 August 2023
Accepted: 24 October 2023
First Online: 29 November 2023
Declarations
:
: The authors declare no competing interests.
: H.M.O. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck Serono GmbH. C.F. declares no conflicts of interest. M.B. declares no conflicts of interest. T.H. received support for attending meetings and/or travel from Takeda and Jansen and participated on a Data Safety Monitoring Board or Advisory Board from Janssen. R.M. received support for attending meetings and/or travel from Takeda and Jansen and participated on a Data Safety Monitoring Board or Advisory Board from Janssen. K.B. declares no conflicts of interest. U.K. declares no conflicts of interest. J.S. received Grants or contracts from Basilea Pharmaceuticals and the German Federal Ministry of Education and Research (BMBF), consulting fees from Gilead and Alvea Vax, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, AbbVie, and Pfizer, support for attending meetings and/ or travel from the German Society for Infectious Diseases and the Meta-Alexander Foundation. He participated on a Data Safety Monitoring Board or Advisory Board by Alvea Vax and Micron Research. M.F. declares no conflicts of interest. A.D,D, declares no conflicts of interest. B-N.B. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from from incyte and support for attending meetings and/or travel from Kite/Gilead and Medac. E.K. declares no conflicts of interest. O.T. declares no conflicts of interest. A.K. received support for attending meetings and/or travel from Gilead and AbbVie and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead. C.dA. declares no conflicts of interest. S.G. declares no conflicts of interest. J.S. declares no conflicts of interest. N.S. declares no conflicts of interest. G.S. declares no conflicts of interest. J.K.R. received Consulting fees from AbbVie, Boehringer, Gilead, Merck, and ViiV, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, Janssen, Merck, and ViiV; he has Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for EACS. C.P.S declares no conflicts of interest. P.B. declares no conflicts of interest. J.P. declares no conflicts of interest. B-E.O.J. received Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, ViiV, GSK, Pfizer, Janssen-Cilag, Fresenius Medical care, and the Falk Foundation, support for attending meetrings and/ or travel from Gilead; he participated on a Data Safety Monitoring Board or Advisory Board from Gilead, ViiV, and Theratechnologies; he has Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Scientific Secretary for German AIDS Society and member of STAKOB and COVRIIN working groups at Robert-Koch-Institute. T.L. declares no conflicts of interest. C.B. received Grants or contracts from DZIF, DFG, and NEAT ID, Consulting fees from Abbvie, Gilead, JnJ, MSD, and ViiV, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Gilead, JnJ, MSD, and ViiV, support for attending meetings and/or travel from Abbvie, Gilead, JnJ, MSD, and ViiV; he participated on a Data Safety Monitoring Board or Advisory Board from Mavmet Study. A.H. declares no conflicts of interest. O.A.C. reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Stocks from CoRe Consulting, EasyRadiology; Other interests from DGHO, DGI, ECMM, EHA, ISHAM, MSG-ERC, Wiley. M.B.M. received Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, Pfizer, Gilead Sciences, AstraZeneca, and Virology Education, and support for attending meetings and/or travel from Gilead.
: Due to the retrospective study design, ethical approval and/or patient information was not required according to the North Rhine-Westphalian legislation.